🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "major milestone" in the battle against drug-resistant strains of the bacteria, according to researchers.

A Global Public Health Issue

Gonorrhoea infections are escalating around the world, with data suggesting in excess of 82 million new cases each year. Particularly high rates are reported in the African continent and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. Across England, cases have reached a all-time high, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an important and timely advancement in the face of growing infection rates, increasing antimicrobial resistance and the very limited available drugs currently available.”

Medical experts are increasingly worried about the surge in drug-resistant strains. The World Health Organization has designated it as a "high-priority threat". Ongoing monitoring revealed that resistance to primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Therapies Receive Authorization

Zoliflodacin, alternatively called Nuzolvence, was authorized by the US FDA in December for combating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers believe that targeted use of this new drug will help slow the emergence of superbugs.

Another new antibiotic, originating from the pharmaceutical company GSK, also received approval in the same week. This treatment, which is also used to treat urinary tract infections, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Development Model

This new treatment was the result of a innovative non-profit model for drug creation. The charitable organization GARDP partnered with the drug firm Innoviva to bring it to fruition.

“This milestone marks a major breakthrough in the treatment of highly resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Clinical Trial Data and Worldwide Availability

Based on data released by a prominent scientific publication, the new drug successfully treated over nine in ten of genital gonorrhoea infections. This establishes an equal footing with the typical regimen, which combines two antibiotics. The trial enrolled nearly 1,000 patients from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, the non-profit has the rights to license and sell the drug in numerous developing nations.

Medical professionals treating patients have expressed optimism. Access to a one-pill regimen like this is seen as a "game-changer" for managing the epidemic. This is viewed as vital to reduce the burden of the infection for individuals and to stop the proliferation of highly drug-resistant gonorrhoea globally.